Schön, Michael P.

[["dc.bibliographiccitation.artnumber","e51752"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","PLoS ONE"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Singh, Tej Pratap"],["dc.contributor.author","Schoen, Michael Peter"],["dc.contributor.author","Wallbrecht, Katrin"],["dc.contributor.author","Gruber-Wackernagel, Alexandra"],["dc.contributor.author","Wang, X."],["dc.contributor.author","Wolf, Peter"],["dc.date.accessioned","2018-11-07T09:29:09Z"],["dc.date.available","2018-11-07T09:29:09Z"],["dc.date.issued","2013"],["dc.description.abstract","It is thought that a Th1/Th17-weighted immune response plays a predominant role in the pathogenesis of psoriasis. Our findings now indicate a link between IL-9, a Th2 and Th9 cytokine, and Th17 pathway in psoriasis. In K5.hTGF-beta 1 transgenic mice, exhibiting a psoriasis-like phenotype, we found increased IL-9R and IL-9 expression in the skin and intradermal IL-9 injection induced Th17-related inflammation. IL-9 also promoted angiogenesis and VEGF and CD31 overexpression in mice in vivo and increased tube formation of human endothelial cells in vitro. Injecting anti-IL-9 antibody into K5.hTGF-beta 1 transgenic mice not only diminished inflammation (including skin infiltration by T cells, monocytes/macrophages, and mast cells) and angiogenesis but also delayed the psoriasis-like skin phenotype. Notably, injection of anti-psoriatic acting anti-IL17 antibody reduced skin IL-9 mRNA and serum IL-9 protein levels in K5.hTGF-beta 1 transgenic mice and prevented IL-9-induced epidermal hyperplasia and inflammation of the skin of wild type mice. In addition, we observed that IL-9R expression in lesional skin from psoriasis patients was markedly higher than in healthy skin from control subjects. Moreover, IL-9 significantly enhanced IL-17A production by cultured human peripheral blood mononuclear cells or CD4+ T cells, especially in psoriasis patients. Thus, IL-9 may play a role in the development of psoriatic lesions through Th17-associated inflammation and angiogenesis."],["dc.identifier.doi","10.1371/journal.pone.0051752"],["dc.identifier.isi","000314707700006"],["dc.identifier.pmid","23335955"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8552"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/30951"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Public Library Science"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 2.5"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.5"],["dc.title","Involvement of IL-9 in Th17-Associated Inflammation and Angiogenesis of Psoriasis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","410"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Clinical Investigation"],["dc.bibliographiccitation.lastpage","421"],["dc.bibliographiccitation.volume","121"],["dc.contributor.author","Zibert, John R."],["dc.contributor.author","Wallbrecht, Katrin"],["dc.contributor.author","Schon, Margarete"],["dc.contributor.author","Mir, Lluis M."],["dc.contributor.author","Jacobsen, Grete K."],["dc.contributor.author","Trochon-Joseph, Veronique"],["dc.contributor.author","Bouquet, Celine"],["dc.contributor.author","Villadsen, Louise S."],["dc.contributor.author","Cadossi, Ruggero"],["dc.contributor.author","Skov, Lone"],["dc.contributor.author","Schon, Michael P."],["dc.date.accessioned","2018-11-07T09:01:32Z"],["dc.date.available","2018-11-07T09:01:32Z"],["dc.date.issued","2011"],["dc.description.abstract","Dysregulated angiogenesis is a hallmark of chronic inflammatory diseases, including psoriasis, a common skin disorder that affects approximately 2% of the population Studying both human psoriasis in 2 complementary xenotransplantation models and psoriasis-like skin lesions in transgenic mice with epidermal expression of human TGF-beta 1, we have demonstrated that antiangiogenic non-viral somatic gene therapy reduces the cutaneous microvasculature and alleviates chronic inflammatory skin disorders Transient muscular expression of the recombinant disintegrin domain (RDD) of metargidin (also known as ADAM-15) by in vivo electroporation reduced cutaneous angiogenesis and vascularization in all 3 models As demonstrated using red fluorescent protein-coupled RDD, the treatment resulted in muscular expression of the gene product and its deposition within the cutaneous hyperangiogenic connective tissue High-resolution ultrasound revealed reduced cutaneous blood flow in vivo after electroporation with RDD but not with control plasmids In addition, angiogenesis- and inflammation-related molecular markers, keratinocyte proliferation, epidermal thickness, and clinical disease scores were downregulated in all models Thus, non-viral antiangiogenic gene therapy can alleviate psoriasis and may do so in other angiogenesis-related inflammatory skin disorders"],["dc.identifier.doi","10.1172/JCI41295"],["dc.identifier.isi","000285892300042"],["dc.identifier.pmid","21135506"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6284"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/24453"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Investigation Inc"],["dc.relation.issn","0021-9738"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Halting angiogenesis by non-viral somatic gene therapy alleviates psoriasis and murine psoriasiform skin lesions"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","324"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Dermatology"],["dc.bibliographiccitation.lastpage","328"],["dc.bibliographiccitation.volume","226"],["dc.contributor.author","Kaune, Kjell Matthias"],["dc.contributor.author","Haas, Ellen"],["dc.contributor.author","Jantke, Maren"],["dc.contributor.author","Kramer, Franz-Josef"],["dc.contributor.author","Gruber, Rudolf"],["dc.contributor.author","Thoms, Kai-Martin"],["dc.contributor.author","Zutt, Markus"],["dc.contributor.author","Schön, Michael P."],["dc.date.accessioned","2018-11-07T09:29:38Z"],["dc.date.available","2018-11-07T09:29:38Z"],["dc.date.issued","2013"],["dc.description.abstract","Background: Concepts of reconstruction of intraoral structures may often include the transfer of flaps composed of external skin with hairs. Given that intraoral hair growth following myocutaneous flaps can cause discomfort, there is a need for effective treatments to relieve cancer patients of these symptoms. Objective: To describe the successful epilation of hairy intraoral flaps using Nd:YAG laser emitting a wavelength of 1,064 nm. Methods: We performed an interdisciplinary prospective clinical study with 9 patients suffering from intraoral hair growth after plastic reconstruction of a hairy donor site due to cancer. Eight male and one female patients were treated with 1-4 sessions of Nd:YAG laser at 5-15-week intervals. Results: Laser treatment resulted in effective hair reduction in 8/9 patients regardless of flap type. In 5/9 patients a hair clearance of > 90% could be achieved, whereas laser treatment was ineffective in one male with white hair. Patients were very satisfied with the outcome and no side effects could be observed. Conclusion: Nd:YAG laser therapy appears to be a successful therapeutic option for patients suffering from growth of dark hair in the oral cavity after plastic reconstruction using a hairy donor site. (C) 2013 S. Karger AG, Basel"],["dc.identifier.doi","10.1159/000350685"],["dc.identifier.isi","000324547600007"],["dc.identifier.pmid","23838394"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10820"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/31086"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","S. Karger AG"],["dc.relation.eissn","1421-9832"],["dc.relation.issn","1018-8665"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Successful Nd:YAG Laser Therapy for Hair Removal in the Oral Cavity after Plastic Reconstruction Using Hairy Donor Sites"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","795"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Journal der Deutschen Dermatologischen Gesellschaft"],["dc.bibliographiccitation.lastpage","807"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Schön, Michael P."],["dc.contributor.author","Berking, Carola"],["dc.contributor.author","Biedermann, Tilo"],["dc.contributor.author","Buhl, Timo"],["dc.contributor.author","Erpenbeck, Luise"],["dc.contributor.author","Eyerich, Kilian"],["dc.contributor.author","Eyerich, Stefanie"],["dc.contributor.author","Ghoreschi, Kamran"],["dc.contributor.author","Goebeler, Matthias"],["dc.contributor.author","Ludwig, Ralf J."],["dc.contributor.author","Schäkel, Knut"],["dc.contributor.author","Schilling, Bastian"],["dc.contributor.author","Schlapbach, Christoph"],["dc.contributor.author","Stary, Georg"],["dc.contributor.author","Stebut, Esther"],["dc.contributor.author","Steinbrink, Kerstin"],["dc.date.accessioned","2021-04-14T08:24:09Z"],["dc.date.available","2021-04-14T08:24:09Z"],["dc.date.issued","2020"],["dc.description.abstract","Summary The COVID‐19 pandemic caused by SARS‐CoV‐2 has far‐reaching direct and indirect medical consequences. These include both the course and treatment of diseases. It is becoming increasingly clear that infections with SARS‐CoV‐2 can cause considerable immunological alterations, which particularly also affect pathogenetically and/or therapeutically relevant factors. Against this background we summarize here the current state of knowledge on the interaction of SARS‐CoV‐2/COVID‐19 with mediators of the acute phase of inflammation (TNF, IL‐1, IL‐6), type 1 and type 17 immune responses (IL‐12, IL‐23, IL‐17, IL‐36), type 2 immune reactions (IL‐4, IL‐13, IL‐5, IL‐31, IgE), B‐cell immunity, checkpoint regulators (PD‐1, PD‐L1, CTLA4), and orally druggable signaling pathways (JAK, PDE4, calcineurin). In addition, we discuss in this context non‐specific immune modulation by glucocorticosteroids, methotrexate, antimalarial drugs, azathioprine, dapsone, mycophenolate mofetil and fumaric acid esters, as well as neutrophil granulocyte‐mediated innate immune mechanisms. From these recent findings we derive possible implications for the therapeutic modulation of said immunological mechanisms in connection with SARS‐CoV‐2/COVID‐19. Although, of course, the greatest care should be taken with patients with immunologically mediated diseases or immunomodulating therapies, it appears that many treatments can also be carried out during the COVID‐19 pandemic; some even appear to alleviate COVID‐19."],["dc.identifier.doi","10.1111/ddg.14169"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81179"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1610-0387"],["dc.relation.issn","1610-0379"],["dc.rights","This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes."],["dc.title","COVID‐19 and immunological regulations – from basic and translational aspects to clinical implications"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","528"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Journal der Deutschen Dermatologischen Gesellschaft"],["dc.bibliographiccitation.lastpage","530"],["dc.bibliographiccitation.volume","20"],["dc.contributor.affiliation","Julius, Katharina; 1\r\nDepartment of Dermatology\r\nVenereology\r\nand Allergology\r\nUniversity Medical Center\r\nGöttingen Germany"],["dc.contributor.affiliation","Kromer, Christian; 1\r\nDepartment of Dermatology\r\nVenereology\r\nand Allergology\r\nUniversity Medical Center\r\nGöttingen Germany"],["dc.contributor.affiliation","Schnabel, Viktor; 1\r\nDepartment of Dermatology\r\nVenereology\r\nand Allergology\r\nUniversity Medical Center\r\nGöttingen Germany"],["dc.contributor.affiliation","Vlahova, Lyubomira; 1\r\nDepartment of Dermatology\r\nVenereology\r\nand Allergology\r\nUniversity Medical Center\r\nGöttingen Germany"],["dc.contributor.affiliation","Kitz, Julia; 2\r\nInstitute of Pathology\r\nUniversity Medical Center\r\nGöttingen Germany"],["dc.contributor.affiliation","Schön, Michael P.; 1\r\nDepartment of Dermatology\r\nVenereology\r\nand Allergology\r\nUniversity Medical Center\r\nGöttingen Germany"],["dc.contributor.affiliation","Sahlmann, Carsten‐Oliver; 4\r\nInstitute of Nuclear Medicine\r\nUniversity Medical Center\r\nGöttingen Germany"],["dc.contributor.author","Julius, Katharina"],["dc.contributor.author","Kromer, Christian"],["dc.contributor.author","Schnabel, Viktor"],["dc.contributor.author","Vlahova, Lyubomira"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Schön, Michael P."],["dc.contributor.author","Sahlmann, Carsten‐Oliver"],["dc.contributor.author","Kretschmer, Lutz"],["dc.date.accessioned","2022-04-01T10:03:27Z"],["dc.date.available","2022-04-01T10:03:27Z"],["dc.date.issued","2022"],["dc.date.updated","2022-06-14T21:15:08Z"],["dc.identifier.doi","10.1111/ddg.14737"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/106172"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-530"],["dc.relation.eissn","1610-0387"],["dc.relation.issn","1610-0379"],["dc.rights","This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes."],["dc.rights.uri","http://creativecommons.org/licenses/by-nc/4.0/"],["dc.title","Response of metastatic acral melanoma with exon 11 BRAF G469A mutation to BRAF/MEK inhibition"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","818"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Journal der Deutschen Dermatologischen Gesellschaft"],["dc.bibliographiccitation.lastpage","853"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","Schön, Michael P."],["dc.date.accessioned","2022-07-01T07:35:12Z"],["dc.date.available","2022-07-01T07:35:12Z"],["dc.date.issued","2022"],["dc.date.updated","2022-11-11T13:13:49Z"],["dc.description.abstract","Summary\r\nTicks, particularly hard ticks (Ixodidae), which are among the most important vectors of dangerous infectious agents, feed on their hosts for extended periods of time. With this lifestyle, numerous adaptations have evolved in ticks and their hosts, the pharmacological importance of which is increasingly being recognized. Many bioactive substances in tick saliva are being considered as the basis of new drugs.\r\nFor example, components of tick cement can be developed into tissue adhesives or wound closures. Analgesic and antipruritic salivary components inhibit histamine or bradykinin, while other tick‐derived molecules bind opioid or cannabinoid receptors. Tick saliva inhibits the extrinsic, intrinsic, or common pathway of blood coagulation with implications for the treatment of thromboembolic diseases. It contains vasodilating substances and affects wound healing. The broad spectrum of immunomodulatory and immunosuppressive effects of tick saliva, such as inhibition of chemokines or cellular immune responses, allows development of drugs against inflammation in autoimmune diseases and/or infections. Finally, modern vaccines against ticks can curb the spread of serious infections. The medical importance of the complex tick‐host interactions is increasingly being recognized and translated into first clinical applications. Using selected examples, an overview of the mutual adaptations of ticks and hosts is given here, focusing on their significance to medical advance."],["dc.identifier.doi","10.1111/ddg.14821"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112111"],["dc.language.iso","de"],["dc.notes.intern","DOI-Import GROB-581"],["dc.relation.eissn","1610-0387"],["dc.relation.issn","1610-0379"],["dc.rights","This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made."],["dc.rights.uri","http://creativecommons.org/licenses/by-nc-nd/4.0/"],["dc.title","The tick and I: Parasite‐host interactions between ticks and humans"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","12"],["dc.bibliographiccitation.journal","Frontiers in Immunology"],["dc.bibliographiccitation.volume","10"],["dc.contributor.affiliation","Neubert, Elsa; 1Department of Dermatology, Venereology and Allergology, University Medical Center Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","Senger-Sander, Susanne N.; 1Department of Dermatology, Venereology and Allergology, University Medical Center Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","Manzke, Veit S.; 1Department of Dermatology, Venereology and Allergology, University Medical Center Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","Busse, Julia; 1Department of Dermatology, Venereology and Allergology, University Medical Center Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","Polo, Elena; 2Institute of Physical Chemistry, University of Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","Scheidmann, Sophie E. F.; 1Department of Dermatology, Venereology and Allergology, University Medical Center Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","Schön, Michael P.; 1Department of Dermatology, Venereology and Allergology, University Medical Center Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","Kruss, Sebastian; 2Institute of Physical Chemistry, University of Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","Erpenbeck, Luise; 1Department of Dermatology, Venereology and Allergology, University Medical Center Göttingen, Göttingen, Germany"],["dc.contributor.author","Neubert, Elsa"],["dc.contributor.author","Senger-Sander, Susanne N."],["dc.contributor.author","Manzke, Veit S."],["dc.contributor.author","Busse, Julia"],["dc.contributor.author","Polo, Elena"],["dc.contributor.author","Scheidmann, Sophie E. F."],["dc.contributor.author","Schön, Michael P."],["dc.contributor.author","Kruss, Sebastian"],["dc.contributor.author","Erpenbeck, Luise"],["dc.date.accessioned","2019-07-09T11:50:03Z"],["dc.date.available","2019-07-09T11:50:03Z"],["dc.date.issued","2019"],["dc.date.updated","2022-02-09T13:23:16Z"],["dc.description.abstract","The formation of neutrophil extracellular traps (NETs) is an immune defense mechanism of neutrophilic granulocytes. Moreover, it is also involved in the pathogenesis of autoimmune, inflammatory, and neoplastic diseases. For that reason, the process of NET formation (NETosis) is subject of intense ongoing research. In vitro approaches to quantify NET formation are commonly used and involve neutrophil stimulation with various activators such as phorbol 12-myristate 13-acetate (PMA), lipopolysaccharides (LPS), or calcium ionophores (CaI). However, the experimental conditions of these experiments, particularly the media and media supplements employed by different research groups, vary considerably, rendering comparisons of results difficult. Here, we present the first standardized investigation of the influence of different media supplements on NET formation in vitro. The addition of heat-inactivated (hi) fetal calf serum (FCS), 0.5% human serum albumin (HSA), or 0.5% bovine serum albumin (BSA) efficiently prevented NET formation of human neutrophils following stimulation with LPS and CaI, but not after stimulation with PMA. Thus, serum components such as HSA, BSA and hiFCS (at concentrations typically found in the literature) inhibit NET formation to different degrees, depending on the NETosis inducer used. In contrast, in murine neutrophils, NETosis was inhibited by FCS and BSA, regardless of the inducer employed. This shows that mouse and human neutrophils have different susceptibilities toward the inhibition of NETosis by albumin or serum components. Furthermore, we provide experimental evidence that albumin inhibits NETosis by scavenging activators such as LPS. We also put our results into the context of media supplements most commonly used in NET research. In experiments with human neutrophils, either FCS (0.5-10%), heat-inactivated (hiFCS, 0.1-10%) or human serum albumin (HSA, 0.05-2%) was commonly added to the medium. For murine neutrophils, serum-free medium was used in most cases for stimulation with LPS and CaI, reflecting the different sensitivities of human and murine neutrophils to media supplements. Thus, the choice of media supplements greatly determines the outcome of experiments on NET-formation, which must be taken into account in NETosis research."],["dc.identifier.doi","10.3389/fimmu.2019.00012"],["dc.identifier.eissn","1664-3224"],["dc.identifier.pmid","30733715"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15847"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59691"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","Frontiers Media S.A."],["dc.relation.eissn","1664-3224"],["dc.relation.issn","1664-3224"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","Serum and Serum Albumin Inhibit in vitro Formation of Neutrophil Extracellular Traps (NETs)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e1634"],["dc.bibliographiccitation.journal","Cell Death and Disease"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Kramer, Daniela"],["dc.contributor.author","Schoen, M."],["dc.contributor.author","Bayerlova, M."],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Schoen, Michael Peter"],["dc.contributor.author","Zoernig, M."],["dc.contributor.author","Dobbelstein, Matthias"],["dc.date.accessioned","2018-11-07T10:01:17Z"],["dc.date.available","2018-11-07T10:01:17Z"],["dc.date.issued","2015"],["dc.description.abstract","The p53 family and its cofactors are potent inducers of apoptosis and form a barrier to cancer. Here, we investigated the impact of the supposedly inhibitory member of the apoptosis-stimulating protein of p53, iASPP, on the activity of the p53 homolog TAp73, and its cofactors p300 and CBP. We found that iASPP interacted with and stabilized the histone acetyltransferase p300 and its homolog CBP upon cisplatin treatment. Vice versa, iASPP depletion by shRNA resulted in decreased amounts of p300 and CBP, impaired binding of p300 and TAp73 to target site promoters, reduced induction of pro-apoptotic TAp73 target genes, and impaired apoptosis. Mechanistically, we observed that the p300-regulatory E3 ubiquitin ligase BRMS1 could rescue the degradation of p300 and CBP in cisplatin-treated, iASPP-depleted cells. This argues that iASPP stabilizes p300 and CBP by interfering with their BRMS1-mediated ubiquitination, thereby contributing to apoptotic susceptibility. In line, iASPP overexpression partially abolished the interaction of BRMS1 and CBP upon DNA damage. Reduced levels of iASPP mRNA and protein as well as CBP protein were observed in human melanoma compared with normal skin tissue and benign melanocytic nevi. In line with our findings, iASPP overexpression or knockdown of BRMS1 each augmented p300/CBP levels in melanoma cell lines, thereby enhancing apoptosis upon DNA damage. Taken together, destabilization of p300/CBP by downregulation of iASPP expression levels appears to represent a molecular mechanism that contributes to chemoresistance in melanoma cells."],["dc.description.sponsorship","Deutsche Krebshilfe; Wilhelm-Sander Stiftung"],["dc.description.sponsorship","Open Access Publikationsfonds 2015"],["dc.identifier.doi","10.1038/cddis.2015.17"],["dc.identifier.isi","000350575800008"],["dc.identifier.pmid","25675294"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11853"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37982"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Nature Publishing Group"],["dc.relation.issn","2041-4889"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","A pro-apoptotic function of iASPP by stabilizing p300 and CBP through inhibition of BRMS1 E3 ubiquitin ligase activity"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2021"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Cancer Immunology Immunotherapy"],["dc.bibliographiccitation.lastpage","2031"],["dc.bibliographiccitation.volume","61"],["dc.contributor.author","Buhl, Timo"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.contributor.author","Rosenberger, Albert"],["dc.contributor.author","Schardt, Anke"],["dc.contributor.author","Schoen, Michael Peter"],["dc.contributor.author","Haenssle, Holger Andreas"],["dc.date.accessioned","2018-11-07T09:03:57Z"],["dc.date.available","2018-11-07T09:03:57Z"],["dc.date.issued","2012"],["dc.description.abstract","Availability of large quantities of functionally effective dendritic cells (DC) represents one of the major challenges for immunotherapeutic trials against infectious or malignant diseases. Low numbers or insufficient T-cell activation of DC may result in premature termination of treatment and unsatisfying immune responses in clinical trials. Based on the notion that cryopreservation of monocytes is superior to cryopreservation of immature or mature DC in terms of resulting DC quantity and immuno-stimulatory capacity, we aimed to establish an optimized protocol for the cryopreservation of highly concentrated peripheral blood mononuclear cells (PBMC) for DC-based immunotherapy. Cryopreserved cell preparations were analyzed regarding quantitative recovery, viability, phenotype, and functional properties. In contrast to standard isopropyl alcohol (IPA) freezing, PBMC cryopreservation in an automated controlled-rate freezer (CRF) with subsequent thawing and differentiation resulted in significantly higher cell yields of immature and mature DC. Immature DC yields and total protein content after using CRF were comparable with results obtained with freshly prepared PBMC and exceeded results of standard IPA freezing by approximately 50 %. While differentiation markers, allogeneic T-cell stimulation, viability, and cytokine profiles were similar to DC from standard freezing procedures, DC generated from CRF-cryopreserved PBMC induced a significantly higher antigen-specific IFN-gamma release from autologous effector T cells. In summary, automated controlled-rate freezing of highly concentrated PBMC represents an improved method for increasing DC yields and autologous T-cell stimulation."],["dc.description.sponsorship","University Medical Center Gottingen for young researchers"],["dc.identifier.doi","10.1007/s00262-012-1262-0"],["dc.identifier.isi","000310888400012"],["dc.identifier.pmid","22527251"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8798"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25006"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0340-7004"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Controlled-rate freezer cryopreservation of highly concentrated peripheral blood mononuclear cells results in higher cell yields and superior autologous T-cell stimulation for dendritic cell-based immunotherapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","675"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Journal der Deutschen Dermatologischen Gesellschaft"],["dc.bibliographiccitation.lastpage","681"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Lauffer, Felix"],["dc.contributor.author","Eyerich, Kilian"],["dc.contributor.author","Boehncke, Wolf‐Henning"],["dc.contributor.author","Asadullah, Khusru"],["dc.contributor.author","Beissert, Stefan"],["dc.contributor.author","Ghoreschi, Kamran"],["dc.contributor.author","Schön, Michael P."],["dc.date.accessioned","2021-04-14T08:25:27Z"],["dc.date.available","2021-04-14T08:25:27Z"],["dc.date.issued","2020"],["dc.description.abstract","Summary Various immune cells and their messenger substances influence the development of psoriasis. Cytokines of the IL‐17 family are of particular importance. In addition to IL‐17A, which plays a central role in the pathogenesis of psoriasis, other subtypes of the IL‐17 family also have a proinflammatory effect. This review provides an up‐to‐date overview of the immunopathogenesis of psoriasis with regard to the six IL‐17 subtypes, in particular their physiological and pathogenic properties, as well as their significance for psoriasis therapy."],["dc.identifier.doi","10.1111/ddg.14124"],["dc.identifier.eissn","1610-0387"],["dc.identifier.issn","1610-0379"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81633"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1610-0387"],["dc.relation.issn","1610-0379"],["dc.rights","This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes."],["dc.title","Cytokines of the IL‐17 family in psoriasis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]